Specialist cancer treatments
Dr Hiley specialises in multiple advanced treatments and conditions related to different kinds of cancer.
Jump to a section
Chemotherapy for thoracic cancers
Chemotherapy is a common treatment using in treating thoracic (lung) cancer, either as standalone therapy or in combination with other therapies or treatments. Specific chemo medications are used depending on the type of lung cancer, which work to target and destroy the rapidly multiplying cells.
If lung cancer treatment includes chemotherapy, patients may benefit by learning what to expect, both during treatment and afterwards. Different lung cancers require different treatment goals, where chemotherapy may be prescribed alone or in combination with other common approaches, such as radiation therapy and proton beam therapy.
Immunotherapy for thoracic cancers
Immunotherapy is used to treat a variety of cancers, including thoracic or lung cancer. Sometimes referred to as immune-oncology, lung cancer immunotherapy involves the use of specialised medicine to treat lung cancer by calling upon the body’s own immune system and defenses.
Immunotherapy for lung cancer may either be administered on its own or in combination with another or multiple conventional treatments, which can help to vastly improve patient outcomes. Whether a patient has been diagnosed with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) or mesothelioma, Dr Hiley and his compassionate team will determine candidacy in each case for thoracic cancer immunotherapy, improving patients’ chances of living longer and enjoying a normal life.
Targeted therapy for thoracic cancers
In lung cancer, certain cells are unable to work as intended due to changes or ‘mutations’ in the DNA. These mutations, called molecular targets, cause the affected cells to grow out of control. In a condition like lung cancer, the abnormal cancer cells initially form within lung tissues.
Targeted therapy for thoracic (lung) cancers, therefore, is an effective form of treatment as it involves the use of powerful drugs to remedy the genetic abnormalities. The specialised drugs shrink the cancer and halt further growth.
Since no two lung cancers can be the same, targeted therapy for lung cancer has proven to be a revolutionary treatment method. It can help patients enjoy a longer life along with better quality of living. At Dr Hiley’s private practice and the leading-class medical facilities he works out of, patients can easily gain access to such advanced and innovative treatments, including a specific kind of blood test which can easily identify tumour targets in a week or less.
Proton beam therapy for thoracic cancers
Proton beam therapy is a kind of radiotherapy which is given to lung cancer patients a few days each week in small doses. It is distinct to conventional radiotherapy as it uses a different particle.
This has a number of benefits, including not as many side effects when compared to conventional radiotherapy. In fact, in many cases, patients opt for proton beam therapy to escape the often serious side effects brought about by traditional X-ray based radiotherapy.
Proton therapy is effective in treating a variety of cancers, including breast cancer, head and neck cancers, and certain kinds of lung cancer, such as non-small cell lung cancer in early lung cancer patients and those with locally advanced lung cancers. It can, however, also be an effective therapy for treating mesothelioma, and where patients require radiotherapy right after thymic gland enlargement surgery.
Learn more about proton beam therapy for lung cancers.
Radiotherapy
Radiotherapy or radiation therapy is a cancer treatment where high doses of radiation are administered to patients in order to kill cancer cells or shrink tumours (or both).
At relatively low doses, radiation is used to see inside the body to identify the site of the cancer or tumour. At high doses, radiation is used to kill cancer cells or slow down their growth by damaging their DNA.
Radiation therapy may not destroy cancer cells immediately as it can take a few days to a few weeks of treatment before the DNA can be damaged enough for the cancer cells to get destroyed permanently. Once the radiation therapy ends, cancer cells continue to die weeks and even months afterward.
An oncologist will define each patient’s radiotherapy goals according to the type of cancer they have and how far it has spread in a specific region in the body. Radiation therapy may be administered on its own or as part of a tailored programme which includes multiple treatments.
Re-irradiation radiotherapy
Re-irradiation is a term which describes repeat administration of radiotherapy to a region which was previously exposed to radiotherapy – i.e. for locoregional tumour recurrence or second primary cancers being found months or even years after the first course of radiotherapy was administered, and where critical tissues or organs were not damaged as a result.
Re-irradiation radiotherapy (RT) may or may not be a viable treatment for local cancer relapses or second primary ones, although it can be an effective modern radiotherapy technique, depending on the patient’s current symptoms, treatment goals, and recovery outcome.
Re-irradiation radiotherapy requires a comprehensive assessment by an expert oncologist. Dr Hiley is available to consult in order to help patients understand if re-irradiation RT may be useful in helping them manage symptoms of a specific kind of cancer.
Re-irradiation stereotactic ablative body radiotherapy (SABR)
SABR is a highly targeted radiotherapy treatment where a tumour is targeted using radiation beams from varying angles. One of the goals is to deliver fewer treatments than conventional radiotherapy (in most cases), using typically 3, 5, or 8 fractions.
Through this revolutionary treatment, a high dose of radiation can be administered to the tumour where adjoining tissues around the tumour receive minimal radiation. This spares the healthy surrounding tissues undue damage and toxicity.
SABR is a viable alternative treatment option to traditional/systematic therapy where surgery has been ruled out as an unsuitable option; where it has not resulted in marginally positive gains, or; where it has been turned down by the patient or his/her family to the risks associated with it and the long-term side effects of the surgical treatment.
Re-irradiation Stereotactic Ablative Radiotherapy has been successfully used to treat lung tumours in patients who have previously received radiotherapy for stage 1-2 or 3-4 in non-small cell lung cancer. Relatively low doses are administered in 5-6 fractions which can dramatically improve a patient’s control rate and overall survival rate.
Stereotactic ablative body radiotherapy (SABR) – without re-irradiation
SABR can also be delivered as a non-surgical treatment to patients who have not been previously exposed to radiation, and who have centrally located early-stage lung cancer.
Surgery has been traditionally considered the standard care for early stage lung cancer although many patients are ineligible for this due to the presence of co-morbid conditions like cardiovascular disease or chronic obstructive pulmonary disease.
Furthermore, despite more advanced invasive surgical treatments, more than 40% patients are usually readmitted within the first 90 days of surgery where at least 3% remain at a risk of mortality.
This is where SABR is considered to be an effective alternative with high local control rates, as well as a 3-year local control rate of around 90%, which are comparable to results obtained through anatomic lobectomy.
Single fraction stereotactic ablative body radiotherapy (SF SABR)
Several franctionation schemes have proven to be very safe and effective for stereotactic ablative body radiotherapy (SABR), including the SF (single fraction) scheme.
While SABR has been well-established as an effective technique to locally control early stages of non-small cell lung cancer (NSCLC) and pulmonary metastasis, the SF scheme in particular has proven to be a highly cost-effective option for patients, offering them more convenience and comfort, along with greater flexibility in terms of symptomatic management when combined with systemic treatments.
SF SABR has strong evidence, long experience, and sufficient maturity to be reliably administered in patients with peripheral primary non-small cell lung cancer in the early stages, and offers promising long-term outcomes when it comes to treating pulmonary metastases, thus, making it a valid treatment option.
MRI guided stereotactic ablative body radiotherapy (SABR) – MRLinac
MRI-guided SABR for central and ultra-central lesions in the lungs are now a key area of interest and development in the medical sector, proving to be very effective at targeting both central (located within 2cm around the proximal bronchial tree in any direction) and ultra-central (where planning target volume either touches or overlaps the oesophagus, central bronchial tree or pulmonary artery) tumours.
In such cases, SABR is delivered in a fractioned manner, typically using 5 to 8 treatments. A key objective here is to minimise the risk of toxicity caused by the tumour while also ensuring that a therapeutic dose is delivered in order to see high local control rates (up to 90%).
With larger tumour movements, a larger area must be irradiated using the MRLinac MRIdians, which have improved the overall success rate of the treatment.
MR-Linac (magnetic resonance linear accelerator) combines highly precise images and a radiotherapy delivery system which allows real-time imaging with superior soft tissue definition, compared to the current standard of care systems.
Such real-time treatment adaptations allow doctors to integrate functional imaging directly into the radiotherapy pathway, thus, providing patients with more targeted treatments where a greater long-term impact can be had with fewer side effects.
Volumetric modulated arc therapy (VMAT)
VMAT is a kind of radiation therapy used to treat specific kinds of cancer, including lung cancer. During the treatment, a machine rotates around the patient’s body, where multiple energy beams in varying strengths are sent to the cancer cells, thereby destroying tumours in a targeted way.
VMAT is one of the latest forms of EBRT (external beam radiation therapy), delivering calculated doses of radiation to the tumour without ever touching the patient’s body. Today, VMAT is one of the most recommended treatments for targeting various types of lung cancer, including early stage non-small cell lung cancer.
It is particularly well-suited for targeting oddly shaped tumours or those found close to the vital organs or lungs. In fact, many a times, oncologists recommend VMAT radiation therapy if patients are found to have tumours in the lungs which are either close to a vital organ or wrapped around one.
VMAT is considered a more targeted and accurate treatment option compared to the more traditional single beam-based radiotherapy treatments, providing highly precise targeting in low doses to destroy tumours in or around the lungs while minimising side effects to a great degree.
VMAT treatment sessions are also much shorter compared to conventional radiotherapy sessions, often lasting just 2-4 minutes.
Intensity modulated radiotherapy (IMRT)
IMRT is an advanced form of radiation therapy, using powerful energy beams in controlled doses to destroy cancer cells in the lungs. The energy may be derived from protons, X-rays, or other sources, depending on the cancer stage and severity of symptoms.
One of the key advantages of IMRT over other forms of radiotherapy is that the radiation beams can be carefully customised according to each patient’s treatment needs.
The beams can be shaped to match the exact shape of the cancer where they move in an arc to deliver the desired radiation dose. The intensity of every individual beam can be adjusted, making IMRT a highly controlled and precision-based radiation therapy.
IMRT is currently being used to treat tumours and cancers which are benign, and anywhere within the body, including the lungs. With such a targeted delivery method where every radiation beam’s intensity can be individually adjusted, the risk of damaging nearby healthy tissue is minimised as much as possible.
Compared to conventional radiotherapy treatments, IMRT reduces treatment toxicity, even with higher doses, allowing far more effective utilisation of the individual radiation beams to safety target the site of the tumour with significantly fewer side effects.
This advanced method of high-precision radiotherapy brings computer-controlled linear accelerators into play which helps to deliver highly precise radiation doses to malignant cancers or specific areas within the site of the cancer.
Image guided radiotherapy (IGRT)
IGRT makes use of medical imaging equipment to administer accurate and precise radiation doses. It is used to treat tumours in areas that actively move or contract and expand, such as the lungs. It is a very effective radiotherapy for treating tumours which have been found near or around critical organs as well as tissues.
Your oncologist may combine IGRT with IMRT, SABR, or proton beam therapy for optimal results, although the use of multiple treatments, and to what degree they are used, may vary from patient to patient.
During IGRT, high-definition images are taken prior to each radiotherapy session which are then used to improve the accuracy and precision of the treatment. IGRT makes it possible to deliver higher doses of radiation where necessary, which can sometimes make the treatment schedules shorter, while also boosting its overall effectiveness.
IGRT may also be used to control non-cancerous tumours and it is currently being used to treat all kinds of cancers, including lung cancer. Safely using higher doses of radiation to kill tumours in a shorter span of time is one of the key advantages of IGRT, as is preventing harm to healthy tissues around the cancer site, and keeping radiation side effects to a minimum.